This content was created by Everyday Health Media on behalf of an advertiser.
More Information.
Content on this page was created by the Everyday Health Media team and is funded by an advertiser. The content conforms to Everyday Health Media’s editorial standards for accuracy, objectivity, and balance. The advertiser may select the specialty area but does not edit or approve the content.
Metastatic Urothelial Cancer Peer-to-Peer
Variant Histologies in Urothelial Carcinoma
Michael Leapman, MD, of Yale, discusses the treatment of bladder cancer patients with variant histologic subtypes, who are known to be at higher risk of recurrence and metastasis. (2:19)
Q&A: Radical Nephroureterectomy vs Nephron Sparing Surgery in Upper Tract Urothelial Carcinoma
In this interview, Duke researcher John Dudinec discusses his recent study assessing long-term outcomes of patients who received radical nephroureterectomy or nephron-sparing surgery.
In Urothelial Cancer, Genomic Heterogeneity Blocks Precision Oncology
Investigators suggest basing personalized therapeutic choices for urothelial cancers on global assessments, rather than focusing on primary tumors, because of the high degree of genomic variability and discordance in metastatic disease.
A Nontherapeutic Way to Protect Against Certain Cancers?
In a study from Israel, cumulative exposure to residential greenness—living in an area with trees and grass—was shown to lower the risk of developing certain site-specific cancers.
Urothelial Ca: Evaluating Patients’ Performance Status
"Performance status is crucial," says Dr. Chamie, of UCLA. He considers many factors when assessing a patient's ability to tolerate systemic chemotherapy. (0:55)
Metastatic Renal or Urothelial Cancer: How Patients React to ICI Therapy
A prospective, observational study conducted in Japan addressed the usefulness of periodic medical questionnaires combined with laboratory and radiologic examinations in tracking immune-related adverse events associated with immune checkpoint inhibitors.
Newly Diagnosed Bladder Cancer Increases Depression and Anxiety Risk
A longitudinal study of more than 65,000 bladder cancer patients reported a higher incidence of depression/anxiety within 6 months of diagnosis and that persisted for at least 3 years.
The Predictive Value of CKD in a Cohort of Patients with UTUC
The prognostic significance of chronic kidney disease (CKD) in the management of upper tract urothelial carcinoma following radical nephroureterectomy remains unknown. A team of Korean researchers recently attempted to fill that gap.
Metastatic Bladder Cancer: Diagnosis and Survival Differences by Race/Ethnicity
A new study compared survival outcomes among patients with metastatic bladder urothelial carcinoma across racial/ethnic groups with predicted life expectancy, as derived from Social Security Administration life tables.
Q&A with Christopher Hoimes, DO, PhD: New Learnings About the Bladder Tumor Microenvironment
Despite the poor outcomes associated with it, bladder cancer has been understudied. However, new biological insights from the tumor microenvironment of the bladder may enable better treatment strategies.
Glandular Bladder Cancers: Insights into Management
A new retrospective analysis suggests that urothelial carcinoma with glandular differentiation (UC-GD) is similar to urothelial carcinoma not otherwise specified (UC-NOS), while primary bladder and urachal adenocarcinomas are similar to colorectal adenocarcinomas.
In Metastatic Urothelial Carcinoma, Bone Metastasis is an Independent Negative Prognostic Factor
This retrospective analysis showed that the presence of BM is an independent predictor of reduced OS in patients with mUC. These results may inform future research and clinical trial design in order to better understand the molecular pathways of this disease.
Urothelial Cancer: How Do Tertiary Lymphoid Structures Affect the Tumor Immune Landscape?
A new study found that, compared to untreated urothelial tumors, clusters of tertiary lymphoid structures (TLS) showed a distinct immune cell composition in treated tumors. Additionally, the superficial TLS population has more pronounced CD4 T-cell expression than deeper TLS.
Is This a Better Approach to Treating Bladder Cancer?
A study of treatment of muscle-invasive bladder cancer with ultrahypofractionated radiation therapy found that plan-of-the-day (image-guided) therapy was less toxic than a standard plan but still had effective local disease control.
In Advanced/Metastatic Urothelial Cancer, Adverse Events in First-line Chemo
This systematic review and network meta-analysis identifies the chemotherapy regimen with the most generally favorable tolerability profile for the treatment of metastatic urothelial cancer of the bladder.
Immunotherapy + Radiotherapy in Bladder Cancer Treatment
There is an immunomodulatory role of radiation," says Michael Leapman, MD, though the evidence is still in progress. (1:28)
ACR Issues New Recommendations for MIBC Post-Treatment Surveillance
Evidence supports use of magnetic resonance imaging, magnetic resonance urography, computed tomography, or computed tomography urography regardless of whether a patient has had a cystectomy.
MTAP-deficient Metastatic Urothelial Cancer: What’s the Prognosis?
The MTAP gene, located on chromosome 9p21, has been found to be deleted in 27.2% of bladder cancers, along with the deletion of CDKN2A. This MTAP loss in metastatic urothelial cancer has been found to be associated with visceral metastases and poor prognosis.
Metastatic Uro-Oncologic Disease and the COVID-19 Pandemic
How has the COVID-19 pandemic affected metastatic uro-oncologic disease?
Three Cycles of NAC may be Adequate for Muscle-Invasive Bladder Cancer
A retrospective study reveals similar pathologic response and short-term survival for three versus four cycles.
Race and Sex Affect Bladder Cancer Outcomes
Bladder cancer-specific survival was compared across four demographic groups: Black males, Black females, White males, and White females. The investigators discovered Black females had significantly worse outcomes.